Navigation Links
University of Pittsburgh researchers launching trial of new osteoporosis drug
Date:1/14/2010

PITTSBURGH, Jan. 14 Endocrinologists at the University of Pittsburgh School of Medicine and UPMC are launching a human trial of a new drug that their research indicates holds great promise for building bones weakened by osteoporosis.

For the study, 105 participants will be randomly assigned to receive either teriparitide ( Forteo), a drug that already is FDA-approved for osteoporosis treatment, or an experimental agent called parathyroid hormone-related protein (PTHrP), explained principal investigator Mara J. Horwitz, M.D., an assistant Professor of Medicine in the Division of Endocrinology and Metabolism, Pitt School of Medicine, and a practicing metabolic bone specialist at UPMC.

"We are very eager to find out how this new drug compares to a therapy that is currently available," Dr. Horwitz said. "Our previous studies suggest that it may increase bone density more dramatically with fewer side effects, but this is the first head-to-head comparison."

On the cellular level, bone is constantly being broken down, a process known as resorption, and then rebuilt. In osteoporosis, this balancing act is off-kilter, leaving bones less dense and more vulnerable to fracture. Many drugs, such as alendronate (Fosamax), and raloxifene (Evista), work by decreasing bone resorption. They can improve bone density by two to 10 percent over several years to a decade and reduce fractures, but many patients' bone density already has been reduced by half when treatment begins.

Another kind of agent works on the other end of the bone metabolism see-saw: it promotes the creation of new bone. Teriparitide, a form of naturally occurring parathyroid hormone, currently is the only FDA-approved anabolic or bone-building agent in the United States. The experimental drug PTHrP, another protein made naturally by the body, also is an anabolic agent and appears to be unique in its ability to stimulate bone formation without simultaneously increasing bone breakdown. Both drugs are given as daily injections.

"When we studied PTHrP several years ago in small numbers of postmenopausal women with osteoporosis, we found that bone density increased by nearly 5 percent after only three months of treatment," said senior investigator Andrew F. Stewart, M.D., professor and chief of the Division of Endocrinology and Metabolism, Department of Medicine, Pitt School of Medicine. "And even at the highest doses, the side effects were negligible."

In findings published online last week in the Journal of Clinical Endocrinology and Metabolism, Drs. Horwitz and Stewart and their colleagues identified the maximum tolerable dose and therapeutic window of PTHrP. In this study, they were also able to show that PTHrP, at the tolerable doses, stimulated bone formation after only three weeks of treatment.


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. New spider species discovered by University of Haifa scientists
2. University Hospitals Case Medical Center testing gene therapy for Alzheimers disease
3. Uniform method to interpret autism spectrum disorders is defined at Ben-Gurion University
4. Michigan State University study sheds light on microscopic flower petal ridges
5. Boston University reseachers develop faster, cheaper DNA sequencing method
6. University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium
7. Case Western Reserve University grants option to startup Thermalin Diabetes Inc.
8. Lehigh University professor receives Astellas Award for arsenic groundwater remediation efforts
9. University of Texas Southwestern Medical Center researcher wins Avanti Award in lipids
10. University of Washington professor garners Avanti Young Investigator Award
11. University of California, San Francisco, researcher receives ASBMB-Merck Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... ... 17, 2017 , ... Academy of Model Aeronautics (AMA), the ... of unmanned aircraft systems (UAS), are launching a joint program to promote safe ... support educational outreach efforts. , AMA and DJI will collaborate on other potential ...
(Date:2/16/2017)... MENLO PARK, Calif. and ... -- Longitude Capital, a private investment firm focused on ... today announced the promotion of Josh Richardson ... Richardson focuses on investments in biotechnology companies.  He ... and has played important roles in Longitude,s investments ...
(Date:2/16/2017)... 2017   Biostage, Inc. (Nasdaq: ... developing bioengineered organ implants to treat cancers and other ... today the closing on February 15, 2017 of its ... stock and warrants to purchase 20,000,000 shares of common ... offering was priced at $0.40 per share of common ...
(Date:2/16/2017)... Malden, MA (PRWEB) , ... February 16, 2017 ... ... viscoelastic 4-level cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed ... The procedure was performed on a 55-year-old practicing female physician suffering from degenerative ...
Breaking Biology Technology: